Ippato 5135 Proceedings out on company in the du Solected in the Year report disclosed the following information is footho White PROBLEMS Loyal Proceedings and contingencies Various limita claims, proceeding and enten horien ar pending against the Company and certain of its subsidiaries in accordance with SFAS No. S Accounting for contingencies, the Company records accrual for such contingencies when probable that a fiability will be incurred and the amount of tons can be reasonably o mated. These matters involve antitrunt, securities, patent infringements, the Employee Retire ment income Security Act of 1974, as amended (ERISA), pricing, sales and marketing practices environmental health and safety matters, product lability and insurance coverage. The mou grilliant of these matters are described on the next page Plavi Litigation The Company's U.S. territory partnership under its alliance with Sanofi is a plant in three pending patent infringement lawsuits instituted in the US District Court for the Southern District of New York. Plaintiffs infringement position is based on doendantstilling of the Abbreviated New Drug Application (ANDA) with the FDA scaling approval to sell generic clopido grel bisulfate prior to the expiration of the composition of matter patent in Year 9. Plavix is currently the Company's largest product ranked by not sales. Net sales of Plave were approximately $8.3 billion and $2.5 billion for the years ended December 31, Year 2 nd Year 1, respectively. Loss of market exclusivity of Plavix and the subsequent development of generic competition would be material to the Company's sales of Plavix and results of operations and cash flows and could be material to its financial condition and liquidity Tequired Historically, the loss of patent protection on a brand name pharmaceutical product has resulted in a 70 per decline in product sales. Assuming that () BMY per protection in Plavix is lost of the Beginning of Year 3. (b) revenue and caring for years old, is the bence of the loss of patent nection, have equaled those of Year 2. and ) er as margin on Plavix is 60 percent estimate revenue and cumings for Year 3. How the cal affect Plavix potent is carried on its balance as in based a S120 million in the event patent protection foss, how should the company reflect this financial statement? held the capital market react to (1) the disclosure that a patient infringement seit invelving Plavix led against BMY and (b) the disclosure that the suit had been lost wony? Ippato 5135 Proceedings out on company in the du Solected in the Year report disclosed the following information is footho White PROBLEMS Loyal Proceedings and contingencies Various limita claims, proceeding and enten horien ar pending against the Company and certain of its subsidiaries in accordance with SFAS No. S Accounting for contingencies, the Company records accrual for such contingencies when probable that a fiability will be incurred and the amount of tons can be reasonably o mated. These matters involve antitrunt, securities, patent infringements, the Employee Retire ment income Security Act of 1974, as amended (ERISA), pricing, sales and marketing practices environmental health and safety matters, product lability and insurance coverage. The mou grilliant of these matters are described on the next page Plavi Litigation The Company's U.S. territory partnership under its alliance with Sanofi is a plant in three pending patent infringement lawsuits instituted in the US District Court for the Southern District of New York. Plaintiffs infringement position is based on doendantstilling of the Abbreviated New Drug Application (ANDA) with the FDA scaling approval to sell generic clopido grel bisulfate prior to the expiration of the composition of matter patent in Year 9. Plavix is currently the Company's largest product ranked by not sales. Net sales of Plave were approximately $8.3 billion and $2.5 billion for the years ended December 31, Year 2 nd Year 1, respectively. Loss of market exclusivity of Plavix and the subsequent development of generic competition would be material to the Company's sales of Plavix and results of operations and cash flows and could be material to its financial condition and liquidity Tequired Historically, the loss of patent protection on a brand name pharmaceutical product has resulted in a 70 per decline in product sales. Assuming that () BMY per protection in Plavix is lost of the Beginning of Year 3. (b) revenue and caring for years old, is the bence of the loss of patent nection, have equaled those of Year 2. and ) er as margin on Plavix is 60 percent estimate revenue and cumings for Year 3. How the cal affect Plavix potent is carried on its balance as in based a S120 million in the event patent protection foss, how should the company reflect this financial statement? held the capital market react to (1) the disclosure that a patient infringement seit invelving Plavix led against BMY and (b) the disclosure that the suit had been lost wony